Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.

Phillip D MonkJody L BrookesVictoria J TearToby N BattenMarcin MankowskiTatjana Adzic-VukicevicMichael G CrooksDavinder P S DosanjhMonica KraftChristopher E BrightlingFelicity J GabbayStephen T HolgateRatko DjukanovicTom M A Wilkinson

Published in: ERJ open research (2023)

Although the primary objective of the study was not met, SNG001 had a favourable safety profile, and the key secondary end-points analysis suggested that SNG001 may have prevented progression to severe disease.

Keyphrases

phase iii
clinical trial
sars cov
coronavirus disease
open label
early onset
randomized controlled trial
immune response
phase ii
tyrosine kinase